SMLR - Semler Scientific: Great Product Can Still Thrive Post Medicare Advantage
2024-05-08 12:20:13 ET
Summary
- Semler Scientific's primary product, QuantaFlo, is a fast and easy-to-use device for diagnosing peripheral arterial disease. Its stock has dropped nearly 50% in value, presenting a potential opportunity for investors.
- Despite losing the support from Medicare Advantage, the untapped total addressable market for PAD remains large.
- While Semler Scientific faces concentration risk and the expiration of its patent, it has the potential for continued growth and trading at a low valuation.
...
Semler Scientific: Great Product Can Still Thrive Post Medicare Advantage